Literature DB >> 25760529

A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development.

Shingo Oda1, Tatsuki Fukami2, Tsuyoshi Yokoi1, Miki Nakajima3.   

Abstract

UDP-glucuronosyltransferase (UGT) and esterases are recognized as the most important non-P450 enzymes because of their high contribution to drug metabolism. UGTs catalyze the transfer of glucuronic acid to hydroxyl, carboxyl, or amine groups of compounds, whereas esterases hydrolyze compounds that contain ester, amide, and thioester bonds. These enzymes, in most cases, convert hydrophobic compounds to water-soluble metabolites to facilitate the elimination of compounds from the body. Information about these enzymes is steadily increasing, although our knowledge is still behind our understanding of P450. This review gives an overview of recent findings in UGT and esterases studies focusing on tissue distribution, gene regulation, substrate and inhibitor specificity, and species differences. In particular, the absolute protein content of UGT isoforms and esterases in human tissues could be available. In the field of esterases, it is becoming clear that enzymes other than carboxylesterase are involved in drug hydrolysis. In addition, there is an interesting interplay between UGTs and esterases in the formation and hydrolytic deglucuronidation of acyl-glucuronide, which is considered to be a reactive metabolite. With the growing awareness of the importance of non-P450 enzymes in drug development, issues that should be resolved are discussed.
Copyright © 2014 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carboxylesterase; Drug development; Drug metabolism; Enzyme induction; Enzyme inhibitors; Gene expression; Substrate; UDP-glucuronosyltransferase

Mesh:

Substances:

Year:  2014        PMID: 25760529     DOI: 10.1016/j.dmpk.2014.12.001

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  30 in total

1.  Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016.

Authors:  Anitha Saravanakumar; Armin Sadighi; Rachel Ryu; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447

2.  Metabolic Profile of 3-Acetyl-11-Keto-β-Boswellic Acid and 11-Keto-β-Boswellic Acid in Human Preparations In Vitro, Species Differences, and Bioactivity Variation.

Authors:  Yonglei Cui; Xiangge Tian; Jing Ning; Chao Wang; Zhenlong Yu; Yan Wang; Xiaokui Huo; Lingling Jin; Sa Deng; Baojing Zhang; Xiaochi Ma
Journal:  AAPS J       Date:  2016-06-21       Impact factor: 4.009

3.  Catechol-O-Methyltransferase and UDP-Glucuronosyltransferases in the Metabolism of Baicalein in Different Species.

Authors:  Ruiya Zhang; Yonglei Cui; Yan Wang; Xiangge Tian; Lu Zheng; HaiJian Cong; Bin Wu; Xiaokui Huo; Chao Wang; BaoJing Zhang; Xiaobo Wang; Zhonghui Yu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

4.  Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient.

Authors:  Eva Dazert; Marco Colombi; Tujana Boldanova; Suzette Moes; David Adametz; Luca Quagliata; Volker Roth; Luigi Terracciano; Markus H Heim; Paul Jenoe; Michael N Hall
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

5.  Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism.

Authors:  Haeyoung Zhang; Abdul Basit; Diana Busch; King Yabut; Deepak Kumar Bhatt; Marek Drozdzik; Marek Ostrowski; Albert Li; Carol Collins; Stefan Oswald; Bhagwat Prasad
Journal:  Biochem Pharmacol       Date:  2018-08-04       Impact factor: 5.858

6.  Delayed treatment with PTBA analogs reduces postinjury renal fibrosis after kidney injury.

Authors:  Nataliya I Skrypnyk; Subramaniam Sanker; Lauren Brilli Skvarca; Tatiana Novitskaya; Clara Woods; Takuto Chiba; Kevin Patel; Natasha D Goldberg; Lee McDermott; Paige N Vinson; M Wade Calcutt; Donna M Huryn; Lawrence A Vernetti; Andreas Vogt; Neil A Hukriede; Mark P de Caestecker
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-09

7.  Normalized Testosterone Glucuronide as a Potential Urinary Biomarker for Highly Variable UGT2B17 in Children 7-18 Years.

Authors:  Haeyoung Zhang; Abdul Basit; Chris Wolford; Kuan-Fu Chen; Andrea Gaedigk; Yvonne S Lin; J Steven Leeder; Bhagwat Prasad
Journal:  Clin Pharmacol Ther       Date:  2020-02-12       Impact factor: 6.875

8.  The Human UGT2B7 Nanodisc.

Authors:  Ian Cook; Anna B Asenjo; Hernando Sosa; Thomas S Leyh
Journal:  Drug Metab Dispos       Date:  2019-12-31       Impact factor: 3.922

9.  Identification and Characterization of CINPA1 Metabolites Facilitates Structure-Activity Studies of the Constitutive Androstane Receptor.

Authors:  Milu T Cherian; Lei Yang; Sergio C Chai; Wenwei Lin; Taosheng Chen
Journal:  Drug Metab Dispos       Date:  2016-08-12       Impact factor: 3.922

Review 10.  An Evolutionary Perspective on the Impact of Genomic Copy Number Variation on Human Health.

Authors:  Marie Saitou; Omer Gokcumen
Journal:  J Mol Evol       Date:  2019-09-14       Impact factor: 2.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.